Francesco Leone

Summary

Affiliation: Institute for Cancer Research and Treatment
Country: Italy

Publications

  1. ncbi request reprint Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells
    Francesco Leone
    Department of Oncological Sciences, University of Torino Medical School, Institute for Cancer Research and Treatment, IRCC Candiolo, Italy
    J Leukoc Biol 74:593-601. 2003
  2. doi request reprint Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience
    Francesco Leone
    University of Turin, Medical Oncology Department, Institute for Cancer Research and Treatment, Candiolo, Italy
    Cancer 119:277-84. 2013
  3. ncbi request reprint Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors
    Francesco Leone
    Division of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment, Turin, Italy
    Biol Blood Marrow Transplant 12:68-74. 2006
  4. ncbi request reprint Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma
    Francesco Leone
    Department of Clinical Oncology, Unit of Pathology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    Clin Cancer Res 12:1680-5. 2006
  5. doi request reprint Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
    Giuliana Cavalloni
    Department of Medical Oncology, University of Turin Medical School, Turin, Italy
    Mol Cancer Ther 11:1528-38. 2012
  6. pmc Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
    Ymera Pignochino
    Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Italy
    BMC Cancer 10:631. 2010
  7. doi request reprint Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab
    Giuliana Cavalloni
    Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Anticancer Drugs 19:689-96. 2008
  8. ncbi request reprint Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach
    Elisa Sperti
    Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo Turin, Italy
    Dis Colon Rectum 49:1596-601. 2006
  9. ncbi request reprint Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study
    Francesco Leone
    Department of Medical Oncology, Piemonte Oncology Foundation, IRCC Candiolo, Candiolo, Italy
    Cancer 119:3429-35. 2013
  10. doi request reprint Biliary tract carcinomas: from chemotherapy to targeted therapy
    Donatella Marino
    Department of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment IRCC, Candiolo, Italy
    Crit Rev Oncol Hematol 85:136-48. 2013

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells
    Francesco Leone
    Department of Oncological Sciences, University of Torino Medical School, Institute for Cancer Research and Treatment, IRCC Candiolo, Italy
    J Leukoc Biol 74:593-601. 2003
    ..Studies in progress aim to clarify the role of c-ErbB-2 in regulation of this process in hematopoietic tissues...
  2. doi request reprint Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience
    Francesco Leone
    University of Turin, Medical Oncology Department, Institute for Cancer Research and Treatment, Candiolo, Italy
    Cancer 119:277-84. 2013
    ..In this study, they evaluated the use of induction chemotherapy followed by a CRT neoadjuvant protocol...
  3. ncbi request reprint Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors
    Francesco Leone
    Division of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment, Turin, Italy
    Biol Blood Marrow Transplant 12:68-74. 2006
    ..Target-based agents against ErbB-2, epidermal growth factor receptor, or both--such as trastuzumab or gefitinib--might increase the efficiency of purging...
  4. ncbi request reprint Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma
    Francesco Leone
    Department of Clinical Oncology, Unit of Pathology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    Clin Cancer Res 12:1680-5. 2006
    ..Therefore, we analyzed EGFR mutations and related pathways in gallbladder and bile duct carcinomas to consider the possible application of these alternative therapeutic strategies...
  5. doi request reprint Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
    Giuliana Cavalloni
    Department of Medical Oncology, University of Turin Medical School, Turin, Italy
    Mol Cancer Ther 11:1528-38. 2012
    ..We propose our results as a basis for the design of saracatinib-based clinical applications...
  6. pmc Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
    Ymera Pignochino
    Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Italy
    BMC Cancer 10:631. 2010
    ..Furthermore, we tested the efficacy of drugs targeting these molecules, as single agents or in combination with gemcitabine, the standard therapeutic agent against BTC...
  7. doi request reprint Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab
    Giuliana Cavalloni
    Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Anticancer Drugs 19:689-96. 2008
    ..G-CSF treatment increases ErbB2 expression in vitro and in vivo enhancing the activity of trastuzumab on BC cell lines inducing apoptosis of BC cells with low or no ErbB2 genomic amplification...
  8. ncbi request reprint Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach
    Elisa Sperti
    Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo Turin, Italy
    Dis Colon Rectum 49:1596-601. 2006
    ..New chemotherapy agents and integrated treatments have improved the prognosis of patients with metastatic colorectal cancer...
  9. ncbi request reprint Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study
    Francesco Leone
    Department of Medical Oncology, Piemonte Oncology Foundation, IRCC Candiolo, Candiolo, Italy
    Cancer 119:3429-35. 2013
    ....
  10. doi request reprint Biliary tract carcinomas: from chemotherapy to targeted therapy
    Donatella Marino
    Department of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment IRCC, Candiolo, Italy
    Crit Rev Oncol Hematol 85:136-48. 2013
    ..In this review we will discuss the clinical experience with systemic treatment for BTC, focusing on future directions with targeted therapies...
  11. ncbi request reprint Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression
    Eliana Perissinotto
    Department of Oncological Sciences and Laboratories of Clinical Oncology, University of Turin Medical School, IRCC Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo, Turin, Italy
    Clin Cancer Res 11:490-7. 2005
    ....
  12. doi request reprint Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience
    Massimo Aglietta
    Division of Medical Oncology, Department of Oncological Sciences, Institute for Cancer Research and Treatment, Candiolo and University of Torino Medical School, Turin, Italy
    Biol Blood Marrow Transplant 15:326-35. 2009
    ..The study of an allogeneic cell based therapy in less advanced patients is warranted...
  13. ncbi request reprint The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005
    Filippo Montemurro
    Unit of Medical Oncology, Institute for Cancer Research and Treatment, IRCC Candiolo, Strada Provinciale 142, 10060 Candiolo, Turin, Italy
    Expert Opin Pharmacother 6:2907-21. 2005
    ..However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005...
  14. ncbi request reprint Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer
    Francesco Paonessa
    Dipartimento di Medicina Sperimentale e Clinica G Salvatore, Università di Catanzaro Magna Graecia, Catanzaro, Italy
    Cancer Res 66:5085-93. 2006
    ..Our findings support this hypothesis and suggest that in affected individuals, hyperactivation of the AP-2 gene through the overexpression of IR may play a key role in breast carcinogenesis...
  15. ncbi request reprint Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma
    Francesco Leone
    J Clin Oncol 25:1145; author reply 1145-6. 2007